Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering

المؤلفون المشاركون

Bandyopadhyay, Dhrubajyoti
Hajra, Adrija
Ashish, Kumar
Qureshi, Arshna
Ghosh, Raktim K.

المصدر

Journal of Lipids

العدد

المجلد 2018، العدد 2018 (31 ديسمبر/كانون الأول 2018)، ص ص. 1-13، 13ص.

الناشر

Hindawi Publishing Corporation

تاريخ النشر

2018-03-25

دولة النشر

مصر

عدد الصفحات

13

التخصصات الرئيسية

الطب البشري
علوم

الملخص EN

PCSK9 inhibitors, monoclonal antibodies, are novel antihypercholesterolemic drugs.

FDA first approved them in July 2015.

PCSK9 protein (692-amino acids) was discovered in 2003.

It plays a major role in LDL receptor degradation and is a prominent modulator in low-density lipoprotein cholesterol (LDL-C) metabolism.

PCSK9 inhibitors are monoclonal antibodies that target PCSK9 protein in liver and inhibiting this protein leads to drastically lowering harmful LDL-C level in the bloodstream.

Despite widespread use of the statin, not all the high-risk patients were able to achieve targeted level of LDL-C.

Using PCSK9 inhibitors could lead to a substantial decrement in LDL-C plasma level ranging from 50% to 70%, either as a monotherapy or on top of statins.

A large number of trials have shown robust reduction of LDL-C plasma level with the use of PCSK9 inhibitors as a monotherapy or in combination with statins in familial and nonfamilial forms of hypercholesterolemia.

Moreover, PCSK9 inhibitors do not appear to increase the risk of hepatic and muscle-related side effects.

PCSK9 inhibitors proved to be a highly potent and promising antihypercholesterolemic drug by decreasing LDL-R lysosomal degradation by PCSK9 protein.

Statin drugs are known to have some pleiotropic effects.

In this article, we are also focusing on the effects of PCSK9 inhibitor beyond LDL-C reduction like endothelial inflammation, atherosclerosis, its safety in patients with diabetes, obesity, and chronic kidney disease, and its influence on neurocognition and stroke.

نمط استشهاد جمعية علماء النفس الأمريكية (APA)

Bandyopadhyay, Dhrubajyoti& Ashish, Kumar& Hajra, Adrija& Qureshi, Arshna& Ghosh, Raktim K.. 2018. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of Lipids،Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1193491

نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)

Bandyopadhyay, Dhrubajyoti…[et al.]. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of Lipids No. 2018 (2018), pp.1-13.
https://search.emarefa.net/detail/BIM-1193491

نمط استشهاد الجمعية الطبية الأمريكية (AMA)

Bandyopadhyay, Dhrubajyoti& Ashish, Kumar& Hajra, Adrija& Qureshi, Arshna& Ghosh, Raktim K.. Cardiovascular Outcomes of PCSK9 Inhibitors: With Special Emphasis on Its Effect beyond LDL-Cholesterol Lowering. Journal of Lipids. 2018. Vol. 2018, no. 2018, pp.1-13.
https://search.emarefa.net/detail/BIM-1193491

نوع البيانات

مقالات

لغة النص

الإنجليزية

الملاحظات

Includes bibliographical references

رقم السجل

BIM-1193491